XNYS · Healthcare · Drug Manufacturers - General
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Q1 2026 | 0.84 | 0.71 | -15.48% | $1.46B | ❌ Miss | -0.45% | +0.53% | +0.68% |
| 2026-02-12 | Q4 2025 | 0.72 | 0.63 | -12.50% | $1.51B | ❌ Miss | +1.43% | +6.52% | -10.06% |
| 2025-11-10 |
| Q3 2025 |
| 0.92 |
| 1.01 |
| +9.78% |
| $1.60B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | 0.92 | 1.00 | +8.70% | $1.59B | ✅ Beat | +1.34% | +7.74% | +15.24% |
| 2025-02-13 | Q4 2024 | 0.87 | 0.90 | +3.45% | $1.59B | ✅ Beat | -6.37% | -3.86% | -4.29% |
| 2024-10-31 | Q3 2024 | 0.90 | 1.03 | +14.44% | $1.58B | ✅ Beat | -3.78% | -14.16% | -17.09% |
| 2024-08-06 | Q2 2024 | 1.11 | 1.12 | +0.90% | $1.61B | ✅ Beat | +2.14% | +8.79% | +14.53% |
| 2024-05-02 | Q1 2024 | 0.93 | 1.22 | +31.18% | $1.62B | ✅ Beat | +0.56% | +5.18% | +9.64% |
Showing last 8 quarters.